News

BioPharma Dive1d
Full Arvinas, Pfizer data confirm potential, limits of ‘Protac’ drug in breast cancer
While vepdegestrant outperformed a standard treatment option in a subtype of patients, the benefit on progression-free ...
Pfizer-Arvinas breast cancer drug tops AstraZeneca's in delaying progression
Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
Pivotal Phase 3 VERITAC-2 clinical trial results presented at ASCO demonstrate 2.9-month improvement in median ...
TipRanks on MSN1d
Arvinas-Pfizer partnership dynamics may shift, says H.C. Wainwright
H.C. Wainwright analyst Andrew Fein notes that Arvinas (ARVN) shared the final data from the VERITAC-2 trial, which the firm sees positioning ...
Pfizer/Arvinas to seek FDA nod for jointly developed cancer therapy in H2
Pfizer (NYSE:PFE) and Arvinas (NASDAQ:ARVN) announced Saturday their plans to submit a new drug application with the Food and ...
The Pharma Letter1d
ASCO: Positive Phase III results for Arvinas and Pfizer's vepdegestrant
Arvinas (Nasdaq: ARVN) and Pfizer (NYSE: PFE) today announced detailed results from the Phase III VERITAC-2 clinical trial ...
Clinical Trials Arena5d
Pfizer and Arvinas gamble to shift breast cancer treatment paradigm
Pfizer’s and Arvinas’ vepdegestrant is an oral proteolysis-targeting chimera (PROTAC) ER degrader which slows tumour growth.
Nasdaq3d
Arvinas and Pfizer Announce Phase 3 VERITAC-2 Trial Results Showing Vepdegestrant Improves Progression-Free Survival in ESR1-Mutant Breast Cancer Patients
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...
Devdiscourse3d
Breakthrough Breast Cancer Treatment by Pfizer and Arvinas Outshines Rival
Clinical trial results reveal an experimental treatment by Pfizer and Arvinas that delays breast cancer progression by over ...
Morningstar4d
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
and NEW YORK, May 31, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN) and Pfizer Inc. (NYSE: PFE) today announced detailed results from the Phase 3 VERITAC-2 clinical trial (NCT05654623 ...